Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk (NVO) Is Considered a Good Investment by Brokers: Is That True?
10:31am, Tuesday, 12'th Mar 2024
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant
07:45am, Tuesday, 12'th Mar 2024
Novo Nordisk is one of the leading developers of weight-loss drugs. It just shared some great early-stage clinical trial data from one of its programs.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
06:56pm, Monday, 11'th Mar 2024
Novo Nordisk (NVO) concluded the recent trading session at $131.24, signifying a -1.38% move from its prior day's close.
Next thing: weight loss funds in the works
05:27pm, Monday, 11'th Mar 2024
Next thing: weight loss funds in the works.
On the Dip: 3 Stocks to Snatch Up Whenever the Market Stumbles
02:20pm, Monday, 11'th Mar 2024
Building a stock investment portfolio isn't easy. One moment, you are tempted to wait for a dip, and another, you want to give in to the temptation of buying a stock at a premium with the hopes that i
Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk
08:01am, Monday, 11'th Mar 2024
Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.
Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks
03:05pm, Sunday, 10'th Mar 2024
The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last year, the global industry for a
Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?
04:33am, Sunday, 10'th Mar 2024
Shares of Novo Nordisk recently rose to a new all-time high in response to clinical trial results for an experimental new weight-management drug named amycretin. Amycretin is a potential first-in-clas
Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.
04:47pm, Saturday, 09'th Mar 2024
Viking Therapeutics recently unveiled positive clinical trial results for its anti-obesity medication. The treatment is in phase 2 trials, but its results suggest it could rival other weight loss drug
The Top 3 Pharma Stocks to Buy in March2024
01:00pm, Saturday, 09'th Mar 2024
Investors' eyes are closely following the massive rally in pharmaceutical stocks amid the red-hot anti-obesity market. In 2024, the projected revenue for the pharma market is estimated to reach $1.15
Wegovy and Zepbound Are King. Who's Coming for Their Crowns.
02:30am, Saturday, 09'th Mar 2024
Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.
Jim Cramer looks at Europe's 'Super 7'
07:46pm, Friday, 08'th Mar 2024
'Mad Money' host Jim Cramer looks at Europe's top performing stocks, deemed the 'Super 7'.
The European 'Super 7' is a great slate of companies, says Jim Cramer
07:42pm, Friday, 08'th Mar 2024
'Mad Money' host Jim Cramer looks at Europe's top performing stocks, deemed the 'Super 7'.
Weight-loss drug Wegovy approved by FDA to cut heart attack, stroke risk
04:14pm, Friday, 08'th Mar 2024
The move confirms that the new class of obesity medications are useful for improving health, not just losing weight.
FDA approves Novo Nordisk's Wegovy for use in reducing heart attack risks
02:18pm, Friday, 08'th Mar 2024
The U.S. FDA has approved Novo Nordisk's Wegovy for use in lowering the risk of stroke and heart attack in overweight or obese adults who are not diabetic, the Danish drugmaker said on Friday.
